LG Chem Ltd
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 051910.KQ | LGLG.F | 003550.KS | 051905.KS | 051630.KS | 373220.KS | |
|---|---|---|---|---|---|---|
| Market cap | — | 6.17B | 14.39T | 1.34T | 85.75B | 80.96T |
| P/E (TTM) | — | 10.0 | — | — | — | — |
| Forward P/E | — | — | — | — | — | — |
| Price/book | — | 0.3 | — | — | — | — |
| Dividend yield | — | 2.34% | 3.30% | 2.83% | — | — |
| 1-year change | −35.93% | +19.73% | +17.82% | −24.24% | +50.30% | −23.49% |
| Today | 0.00% | −2.27% | −0.64% | +1.44% | +7.87% | −2.54% |
The closest companies by business. Prices may be delayed up to 20 min.
Latest news
All 051910.KQ news ›(LEAD) LG Chem swings to Q3 loss on non-operating losses
SEOUL, Nov. 5 (Yonhap) -- LG Chem Ltd., South Korea's leading chemical company, said Thursday it swung to a net loss in the third quarter from a year earlier, largely due to hefty non-operating losses. In the three months that ended in…
Rhythm Pharmaceuticals changes its tune with LG Chem on obesity drug
Rhythm Pharmaceuticals has amended its exclusive license agreement with LG Chem for bivamelagon, an oral small-molecule melanocortin-4 receptor (MC4R) agonist. The changes raise the deal's potential value from $305 million to as much as…
South Korea's LG Chem Q3 Revenue Jumps 34% but Operating Profit Falls 17% as Petrochemicals Swing to Loss
The results were split by business division. Battery subsidiary LG Energy Solution underpinned overall profit on expanded supplies of energy storage systems (ESS) and cylindrical and high-voltage mid-nickel pouch batteries for electric…
LG Chem Expands Rare Obesity Drug Deal to 1.15 Trillion Won
LG Chem expanded its bivamelagon licensing deal with Rhythm Pharmaceuticals to 1.15 trillion won, with record upfront payments of about 600 billion won. LG Chem (051910) has expanded the value of its licensing deal with U.S.-based Rhythm…
LG Chem Raises Bivamelagon Deal Value with U.S.-Based Rhythm
LG Chem announced on Nov. 3 (on Oct. 2, local time) that it agreed to amend the technology export contract regarding the global development and sales of ‘Vivamelagon’, an oral melanocortin-4 receptor (MC4R) agonist, with Rhythm…
LG Chem Expands Obesity Drug Licensing Deal to $855 Million
Deal Value Grows From $305 Million to $855 Million Company to Receive $350 Million in Additional Upfront Payments Through 2029 Positive Phase 2 Results Clear Path to Phase 3 This Year LG Chem (051910.KS) has expanded the global licensing…
LG Chem boosts Rhythm deal as obesity drug advances toward global phase 3
Rhythm, not LG Chem, will shoulder bigger upfronts as Bivamelagon readies for phase 3 and milestones climb LG Chem(051910) expanded the size of the contract for a rare obesity treatment candidate it out-licensed to Rhythm Pharmaceuticals…
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350…
LG Chem to sell 2.5 tln-won stake in battery unit to boost shareholder value
SEOUL, Oct. 28 (Yonhap) -- LG Chem Ltd., South Korea's leading chemical company, said Wednesday it will sell 2.5 trillion won (US$1.87 billion) worth of shares in its battery unit to enhance shareholder value. Following the planned sale,…
LG Chem Expands Business into Four Core Growth Engines
Aiming to triple growth by 2030 with eco-friendly, battery, drug, and specialty sectors LG Chem
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- en.sedaily.com5
- en.yna.co.kr3
- asiae.co.kr2
- bioxconomy.com1
- biz.chosun.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.